You are being directed to ZacksTrade, a division of Zacks & Company and licensed broker-dealer. ZacksTrade and Zacks.com are separate but affiliated companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click
OK. If you do not, click Cancel.
Back to top
Franklin Strategic Biotechnology: (MF: FBDIX)
(MF) As of Sep 22, 2014 06:05 PM ET
Add to portfolio
Zacks MF Rank : 2 - Buy
This is our Mutual Fund rating system that serves as a timeliness indicator for Mutual Fund's over the next 6 months:
1 Strong Buy
5 Strong Sell
Zacks Mutual Fund Rank FAQ - Learn more about the Zacks Mutual Fund Rank
Zacks Mutual Fund Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
General Information as of Aug 31, 2014
%Unrealized Gain YTD
Net Assets (Mil $) 8/31/2014
% of Portfolio
High Yield Bond
Sector / Country Weightings
As of 8/31/2014
% of Portfolio
Top Equity Holdings
(As of 4/30/2014) % of Portfolio
GILEAD SCIENCES INC
BIOGEN IDEC INC
ALEXION PHARMACEUTICALS I 3.11
INCYTE PHARMACEUTICALS IN 2.93
Stock Holding % of Net Assets
Avg. EPS Growth
Avg. Market Value (Mil $)
Chart for Franklin Strategic Biotechnology FBDIX
Zacks News for FBDIX
2011-02-03 01:00 AM
%Max Sales Load
%Max Deferred Load
%Max 12b-1 Fee
%Max Management Fee
The fund was incepted in September 1997 and is managed by Franklin Advisers. The objective of this fund is to seek capital appreciation. The fund invests at least 80% of its net assets in equity securities of biotechnology companies and discovery research firms worldwide, including therapeutics, drug delivery, gene therapy and other select medical companies. The fund invests a substantial portion of its assets in equity securities of smaller capitalization companies, which are generally companies with a market capitalization of less than $1.5 billion at the time of the fund's investment, and invests a small portion of its assets in private or illiquid securities, such as late stage venture capital financings. The fund offers dividends and capital gains annually. There is no guarantee that fund would regularly pay either income dividends or capital gains distributions.
Zacks Research is Reported On:
Zacks Investment Research is an A+ Rated BBB Accredited Business.
Copyright © 2014 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
performance for information about the performance numbers displayed above.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.